NRx Pharmaceuticals, Inc. (NRXP) shares are rising more than 7 percent on Monday morning after the company announced that Zyesami or aviptadil phase 2b/3 clinical trial demonstrated relief from respiratory distress in critical COVID-19 patients.
The company said the additional finding showed an improvement in blood oxygen, indicative of improved lung function, within a day of starting treatment. Further, the company noted that the average difference in Respiratory Distress Ratio between those treated with aviptadil and placebo was both clinically meaningful and statistically significant.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.